BHE pushes the envelope of real-world data analytics with its uniquely powerful solutions. Using cutting-edge data sources and years of research expertise, BHE delivers actionable results that provide insights to support decision making for the life sciences industry, medical groups, and the payer community.
For over 18 years, BHE has provided high-quality, custom research services to provide insights into the value of healthcare services at the population level. Our services include data analytics, models, comparative effectiveness research, and strategic consulting.
BHE continues to advance and innovate in the development and application of technology-enabled, analytic solutions. With years of analytics experience servicing many of the top life science companies, BHE has launched proprietary technology solutions that provide substantial gains in data analysis efficiency, delivering results in hours versus weeks.
BHE has been recognized by Inc. Magazine as one of America’s fastest growing private companies.
Joseph Menzin, Ph.D. is the President of Boston Health Economics, a health analytics research firm that he founded in 1996. He has more than 25 years of experience in the fields of health economics, outcomes research, and health policy. Dr. Menzin spearheaded the development and launch of BHE’s flagship analytics platforms. His particular areas of interest include health informatics, observational research, and simulation modeling. He has authored several dozen papers in medical, pharmacy, and health economics journals across a wide range of subjects from clinical trials to program evaluation. He serves as a reviewer for numerous journals, and is a member of many professional associations. Dr. Menzin has a Bachelor’s degree in Economics from the University of Rochester and earned his doctorate in Economics from Boston University.
Dr. Mark Friedman, MD, serves as Medical Director for Boston Health Economics. He is a part-time practicing internist with more than 20 years of clinical and pharmacoeconomics consulting experience. He has management experience in the formulary and managed care implementation processes and also plays a major role in the design and implementation of clinically-oriented outcomes research studies, including evidence-based medicine studies, clinical-trial–based evaluations, prospective outcomes studies, and economic models. He is a member of the American Board of Internal Medicine and the American College of Physicians. Dr. Friedman is a graduate of Columbia University and attended the Harvard School of Public Health.
Dr. Peter Neumann, ScD, serves as Senior Advisor at Boston Health Economics. He contributes to health policy and health preference studies, with a special emphasis on the role of cost-effectiveness analysis in healthcare decision making, and economic evaluations of medical technologies. Dr. Neumann is a professor at Tufts University School of Medicine as well as Director at the Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies. There, his research focuses on the role of cost-effectiveness analysis in health care decision making. He has conducted numerous economic evaluations of medical technologies, including evaluations of treatments for Alzheimer's disease. He is currently directing a project to develop a comprehensive registry of cost-effectiveness analyses in health care. He has been published widely in medical literature, and is the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005). He is a contributing editor of Health Affairs and is a member of the editorial board of Value in Health. Dr. Neumann is former President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and a trustee of the Society for Medical Decision Making. He has also held various policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University.
Matthew Sussman, MA is Associate Managing Director and Senior Project Manager at Boston Health Economics. Mr. Sussman has over 15 years of business-to-business consulting experience, and more than 8 years of experience in the field of outcomes research. As Senior Project Manager, he has conducted a wide array of outcomes research studies, including cost-effectiveness and budgetary impact analyses, burden of illness analyses, patient-reported outcomes, retrospective databases analyses, clinical trial evaluations, and randomized clinical trials. His experience has spanned a number of disease areas, including chronic respiratory disease, diabetes, cardiovascular disease, infectious diseases, mental disorders, and oncology. He is a member of the International Society of Pharmacoeconomics and Outcomes Research. Mr. Sussman received his undergraduate degree in Business Administration from the University of Michigan and a master’s degree in Economics from Boston University.
Jordan Menzin, BA, serves as Chief Technology Officer at Boston Health Economics. His areas of interest include software design and programming, health informatics, and economic modeling. He has been successful in building and maintaining BHE’s software systems and simulation models. Of note, he led the design and implementation of Instant Health Data (IHD) which enables life sciences companies to perform rapid analysis across disparate data sets. He received his Bachelor's in Economics from McGill University.
Iris Lin, MPA, PhD, is the Director of Health Analytics Solutions at BHE. She has 6 years of consulting experience in the pharmaceutical industry and over 6 years of experience in research and program evaluation including roles at the U.S. Department of Health and Human Services and the Veterans Affairs Health Care System. She has worked on retrospective database analyses, comparative effectiveness studies, randomized controlled trials, Markov models, burden of illness analyses, and patient-reported surveys . Iris has experience in a range of therapeutic areas including cardiovascular, diabetes, respiratory, oncology, thromboembolic disease, neurological disorders, and women’s health. She holds a Bachelor of Science in Economics from the University of Pennsylvania Wharton School, Master of Public Administration in Health Policy and Management from New York University, and PhD in Public Policy and Health Economics from New York University.